IARC Group 1 Pharmaceuticals and Associated Cancer Risks: A Nationwide Population-Based Cohort Study in Korea
Group 1 pharmaceuticals were associated with increased risk of cancer. The results are expected to help establish alternative clinical strategies and policies for patients with clinical indications of group 1 pharmaceuticals, by continuous risk analysis and discussions on the surveillance systems.
Authors
- Hai‐Lin Park (ORCID: https://orcid.org/0000-0003-4229-5700)
- Su‐Yeon Yu (ORCID: https://orcid.org/0000-0001-5488-5068)
- Ho Gyun Shin (ORCID: https://orcid.org/0000-0002-5365-437X)
- Na Rae Lee (ORCID: https://orcid.org/0000-0001-6155-9906)
- Woojin Lim (ORCID: https://orcid.org/0000-0001-8305-0246)
Institutions
- Seoul National University (KR)
- Kangwon National University (KR)
- National Evidenc- based healthcare Collaborating Agency (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-24
- DOI
- https://doi.org/10.4143/crt.2024.1201
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Evidence-based Healthcare Collaborating Agency